Status:
COMPLETED
Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Lead Sponsor:
Imperial College London
Conditions:
Liver Fibrosis
Eligibility:
All Genders
17-70 years
Phase:
PHASE2
Brief Summary
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to respond to anti-viral treatment are often concerned about their ongoing liver disease and are therefore looking ...
Detailed Description
Background: Convincing evidence exists outlining a role for the coagulation system in the pathogenesis of liver fibrosis. In vivo and in vitro studies have suggested a role for thrombin and FXa in ac...
Eligibility Criteria
Inclusion
- Aged \>17 years (male and female)
- HCV infection PCR positive
- ALT \> 40 iu/ml
- Ishak fibrosis score (within last 5 years) \> 2, \< 5
- Informed consent
- Failed antiviral therapy for HCV in last 5 years
Exclusion
- Patients requiring anticoagulation for existing clinical indications
- Active peptic ulcer disease
- Past history of haemorrhagic stroke
- Thrombocytopaenia (platelets count \< 100 x 109 /L)
- Clinical evidence of portal hypertension
- Known cerebrovascular abnormalities;
- HIV antibody positive;
- Alcohol abuse (\>40 unites/week)
- Menhorragia
- Pregnancy
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00180674
Start Date
August 1 2005
End Date
October 1 2006
Last Update
December 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Mary's Hospital NHS Trust
London, United Kingdom, W2 1NY